AI assistant
Dare Bioscience, Inc. — Director's Dealing 2016
Feb 8, 2016
34825_dirs_2016-02-08_6de193f5-99a8-40b9-908a-b583636ca658.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cerulean Pharma Inc. (CERU)
CIK: 0001401914
Period of Report: 2016-02-04
Reporting Person: WALT DAVID R (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-02-04 | Common Stock | P | 4063 | $2.3088 | Acquired | 125079 | Direct |
| 2016-02-05 | Common Stock | P | 4500 | $2.2945 | Acquired | 129579 | Direct |
Footnotes
F1: These purchases were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2015.
F2: Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.26 to $2.35 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average purchase price for shares purchased in multiple transactions. Purchase prices ranged from $2.26 to $2.35 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price.